Navigation Links
Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent
Date:11/11/2011

MUS Element Stent (p=0.49) and 3.1 percent for the half-dose SYNERGY Stent (p=0.25), all presenting as Non-Q-wave MI.  TLR was 1.1 percent for the SYNERGY Stent, 3.1 percent for the PROMUS Element Stent (p=0.62) and 1.0 percent for the half-dose SYNERGY Stent (p=0.62).

The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug combination to create an ultra-thin, uniform coating applied to the outer (abluminal) surface of the stent.  After the drug has been delivered, the bioabsorbable coating is designed to resorb within four months, leaving only a bare-metal stent.  This technology is designed to provide the same degree of restenosis reduction as a conventional drug-eluting stent while offering faster and more complete vessel healing after stent implantation, which could potentially reduce the duration of post-procedure dual antiplatelet therapy.  The SYNERGY Stent features the same proprietary platinum chromium alloy and similar stent design used in the PROMUS Element Stent to enable thinner struts, increased conformability, deliverability and flexibility while reducing recoil and improving visibility.

"Our fourth-generation SYNERGY Stent is designed to offer the performance advantages of our innovative platinum chromium platform while significantly reducing the amount of polymer and drug to which the vessel wall is exposed," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer of Boston Scientific's Cardiology, Rhythm and Vascular Group.  "EVOLVE trial data will be used to support CE Mark approval for SYNERGY, while additional larger studies are planned to further assess clinical event rates and the potential for reduced dual antiplatelet therapy with this novel stent technology.  The SYNERGY Stent demonstrates our ongoing commitment to innovation and clinical science in pursuing the most advanced treatment options for our physician customers and their patients."

In the U.S.,
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 Yisrayl Hawkins, Pastor ... an open letter in light of the Ferguson, Missouri unrest. ... of civil unrest and explains why it has only increased. ... mankind was even created. He says there is a very ... Yisrayl also says there is a set of rules, or ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... June 6 The makers of the WaveSense(TM),line of ... the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose,Monitoring ... with premium,features that consumers can buy at a value ... with added features for increased safety., The Presto ...
... University of Cincinnati (UC), says that cases of Amyotrophic ... first Persian Gulf War were caused by certain events ... exposure and illness is not as widespread as previously ... July issue of Neuroepidemiology. , Ronnie Horner, PhD, lead ...
... Carriage Services, Inc.,(NYSE: CSV ) today announced ... which can be found on Carriage,s website at, ... Profile includes updated,discussions of Carriage,s business, operating and ... The Company & Investment Profile is being ...
... part of its,ongoing efforts to alleviate human ... and Development (LIFE), recently shipped an,entire forty-foot ... Somalia., In partnership with California-based RICE ... Agency for the Horn,of Africa (ARAHA), two ...
... Grubb & Ellis,Healthcare REIT, Inc. today announced ... consisting of 22 office condominiums in,the Manchester-suburb of ... Nutfield Professional Center consists of,approximately 70,000 square feet ... Center was renovated in 1990 and again in ...
... 5 joint statement, the,presiding bishops of the Evangelical Lutheran ... citizens to pray for peace in Sudan, and,they called ... there., The Rev. Mark S. Hanson of the ... Church made their comments in a public statement,following a ...
Cached Medicine News:Health News:New WaveSense Presto(TM) and Pro(TM) Glucose Meters to Simplify Testing 2Health News:UC research shows risk of ALS exposure in Gulf War veterans is time limited 2Health News:Carriage Services Updates Company & Investment Profile 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 3Health News:Lutheran, Episcopal Church Presiding Bishops Urge Prayers for Peace in Sudan 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: